Literature DB >> 9739478

Chronopharmacokinetics. Current status.

B Bruguerolle1.   

Abstract

Absorption, distribution, metabolism and elimination are influenced by many different physiological functions of the body which may vary with time of day. Thus, the pharmacokinetic parameters characterising these different steps, conventionally considered to be constant in time, depend on the moment of drug administration. Time of day has to be regarded as an additional variable influencing the kinetics of a drug. Chronokinetic studies have been reported for many drugs in an attempt to explain chronopharmacodynamic phenomena and demonstrate that the time of administration is a possible factor of variation in the kinetics of a drug. In this paper this is illustrated with the chronopharmacokinetics of cardiovascular and nonsteroidal anti-inflammatory drugs. Time-dependent changes in kinetics may proceed from circadian variations at each step, e.g. absorption, distribution, metabolism and elimination. Thus, circadian variations in gastric acid secretion and pH, motility, gastric emptying time, gastrointestinal blood flow, drug protein binding, liver enzyme activity and/or hepatic blood flow, glomerular filtration, renal blood flow, urinary pH and tubular resorption may play a role in such kinetic variations. New tools, such as new formulation procedures or pumps with constant or programmable delivery rates, now make it possible to deliver a drug at a definite time, or during a definite span of time and at a controlled rate in chronokinetic studies. Microdialysis would be of particular interest in chronopharmacological and chronokinetics studies, but, surprisingly, very few chronobiological studies have been conducted using this technique. With regard to new models and concepts in chronokinetics, pharmacokinetic-pharmacodynamic modelling may be useful, and modelling of the chronopharmacological patterns of drug response and kinetics have been attempted by some authors. Drug chronopharmacokinetic knowledge may be clinically relevant as it may have implications for drug prescription by modulating the distribution of the total daily dose along the 24-hour scale. However, it seems reasonable to consider chronopharmacokinetic studies in specific cases related to patients, illness or the drug itself. When conducting a chronokinetic study it is not only necessary to take into account differences in the time of administration but to also have strict control of all other possible variables which are known to influence pharmacokinetic processes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9739478     DOI: 10.2165/00003088-199835020-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  50 in total

1.  Intragastric pH and pharmacokinetics of intravenous ranitidine during sinusoidal and constant-rate infusions.

Authors:  S W Sanders; A L Bishop; J G Moore
Journal:  Chronobiol Int       Date:  1991       Impact factor: 2.877

2.  Chronopharmacokinetics and cardiovascular effects of nifedipine.

Authors:  B Lemmer; G Nold; S Behne; R Kaiser
Journal:  Chronobiol Int       Date:  1991       Impact factor: 2.877

3.  Effect of diurnal variation on debrisoquine metabolic phenotyping.

Authors:  G L Shaw; R T Falk; N E Caporaso; H J Issaq; R G Kase; S D Fox; M A Tucker
Journal:  J Natl Cancer Inst       Date:  1990-10-03       Impact factor: 13.506

4.  Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects.

Authors:  B Langner; B Lemmer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Chronopharmacokinetics of nicotine.

Authors:  J M Gries; N Benowitz; D Verotta
Journal:  Clin Pharmacol Ther       Date:  1996-10       Impact factor: 6.875

6.  [Medical advertising and chronopharmacology].

Authors:  B Bruguerolle; A Reinberg; F Lévi
Journal:  Biomed Pharmacother       Date:  1986       Impact factor: 6.529

7.  Circadian changes in the absorption and elimination of theophylline in patients with bronchial obstruction.

Authors:  T Uematsu; F Follath; S Vozeh
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Time dependent changes in the pharmacokinetics of aspirin.

Authors:  A Markiewicz; K Semenowicz
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-10

9.  The effect of age on diurnal variation in the pharmacokinetics of propranolol in hypertensive subjects.

Authors:  T Shiga; A Fujimura; T Tateishi; K Ohashi; A Ebihara
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  [Circadian rhythms in the urinary excretion of salicylate (chronopharmacokinetics) in healthy adults].

Authors:  A Reinberg; J Clench; J Ghata; F Halberg; C Abulker; J Dupont; Z Zagula-Mally
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1975-04-14
View more
  24 in total

1.  Multiplicative dependence of the first order rate constant and its impact on clinical pharmacokinetics and bioequivalence.

Authors:  Pietro Fagiolino
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Jan-Mar       Impact factor: 2.441

Review 2.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships.

Authors:  Pietro Fagiolino; Rosa Eiraldi; Marta Vázquez
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Indirect pharmacodynamic models for responses with circadian removal.

Authors:  Vivaswath S Ayyar; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-01-29       Impact factor: 2.745

Review 5.  Circadian rhythms have broad implications for understanding brain and behavior.

Authors:  Rae Silver; Lance J Kriegsfeld
Journal:  Eur J Neurosci       Date:  2014-05-05       Impact factor: 3.386

Review 6.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

7.  Influence of the Time of Intravenous Administration of Paracetamol on its Pharmacokinetics and Ocular Disposition in Rabbits.

Authors:  Agnieszka Karbownik; Agnieszka Bienert; Włodzimierz Płotek; Tomasz Grabowski; Magdalena Cerbin-Koczorowska; Anna Wolc; Edmund Grześkowiak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

Review 8.  Chronopharmacokinetics of ciclosporin and tacrolimus.

Authors:  Massimo Baraldo; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 9.  Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action.

Authors:  Siddharth Sukumaran; Richard R Almon; Debra C DuBois; William J Jusko
Journal:  Adv Drug Deliv Rev       Date:  2010-06-11       Impact factor: 15.470

10.  Tadalafil pharmacokinetics in healthy subjects.

Authors:  S Thomas Forgue; Beverley E Patterson; Alun W Bedding; Christopher D Payne; Diane L Phillips; Rebecca E Wrishko; Malcolm I Mitchell
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.